PROFILPELAJAR.COM

ETX-155

ETX-155
Clinical data
Other namesETX155
Routes of
administration		Oral[1][2]
Drug classGABAA receptor positive allosteric modulator; Neurosteroid
Pharmacokinetic data
Elimination half-life24–40 hours[3][4]

ETX-155 is a GABAA receptor positive allosteric modulator and neurosteroid which is or was under development for the treatment of depressive disorders, seizures, and fibromyalgia.[1][5][2][3][4] It is taken orally and has an elimination half-life of 24 to 40 hours.[1][2][3][4] The drug produces antidepressant-like, anxiolytic-like, and anticonvulsant effects in rodents.[3][4] Side effects of ETX-155 in humans include somnolence, fatigue, dizziness, and headache.[3][4] ETX-155 was originated by Athenen Therapeutics and is or was under development by Climb Bio and/or Eliem Therapeutics.[1][5][2] As of October 2024, development of the drug for all indications has been suspended or discontinued.[1][5][2] It reached phase 1 clinical trials prior to the suspension or discontinuation of its development.[1][5][2]

See also

References

  1. ^ a b c d e f "ETX 155". AdisInsight. 8 October 2024. Retrieved 18 May 2026.
  2. ^ a b c d e f "ETX-155 Drug Profile". Ozmosi. 1 January 1900. Retrieved 18 May 2026.
  3. ^ a b c d e Perucca E, White HS, Bialer M (September 2023). "New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development". CNS Drugs. 37 (9): 781–795. doi:10.1007/s40263-023-01025-4. PMC 10501930. PMID 37603261.
  4. ^ a b c d e Versavel M (June 2022). "ETX-155, A novel GABAA positive allosteric modulator". Presentation given at the 2022 Epilepsy Foundation Pipeline Conference. Santa Clara, CA: Eliem Therapeutics, Inc.
  5. ^ a b c d "Delving into the Latest Updates on ETX-155 with Synapse". Synapse. 9 May 2026. Retrieved 18 May 2026.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.